A Non-invasive Intracranial Pressure (nICP) Monitoring System

Sponsor
Crainio Ltda (Industry)
Overall Status
Completed
CT.gov ID
NCT05632302
Collaborator
City, University of London (Other), Barts & The London NHS Trust (Other), National Institute for Health Research, United Kingdom (Other)
40
1
1
18
2.2

Study Details

Study Description

Brief Summary

Researchers have developed a probe that contains infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries. Changes in the extramural arterial pressure affect the morphology of the recorded optical pulse, so analysis of the acquired signal using an appropriate algorithm could enable the calculation of the intracranial pressure noninvasively (nICP), which would be displayed to clinicians continuously.

This pilot study is the first evaluation of the device in patients in who the gold standard comparator of invasive ICP was available. The acquisition of pulsatile optical signals was performed for up to 48 hours in each of the 40 patients who were undergoing invasive ICP monitoring as part of their normal medical treatment.

Features of the optical signals would be analysed offline. A machine vector support algorithm would be implemented, with the aim of estimating ICP noninvasively and compared to the gold standard of synchronously acquired invasive ICP data.

Condition or Disease Intervention/Treatment Phase
  • Device: nICP
N/A

Detailed Description

Traumatic brain injury (TBI) is the most common cause of death and disability in the under 40 age group both in the United Kingdom and worldwide, and prevalence is increasing. The mainstay of severe TBI management is intracranial pressure (ICP) measurement. ICP is defined as the pressure within the skull and brain. TBI often causes a rise in ICP as the brain swells within the rigid skull and therapy is directed at keeping this pressure at an acceptable level with medications or surgery. Very high ICP may lead to further brain damage resulting in increased disability or death.

Existing techniques to measure ICP involve placing an electrical sensor into the brain tissue through a small hole drilled in the skull. This procedure risks infection and bleeding into the brain and can only be performed by a neurosurgeon. Therefore, there is a vital demand to develop non-invasive technologies that will allow measuring the ICP without inserting a sensor in the brain. This technology will decrease the risks, permit monitoring outside the hospital (eg in an ambulance) and reduce the costs. It will also increase the indication for ICP monitoring to include other conditions (e.g. stroke or brain tumours) which are not currently monitored.

The proposed non-invasive ICP (nICP) monitor works by shining a harmless light into the brain through the skull. The developed sensor was attached to the skin of the forehead and recorded optical signals (known as photoplethysmography (PPG)) from the brain, which are related to changes in the ICP. This pilot aims to build the first clinical database of nICP signals in intensive care patients. The acquisition of an extensive set of signals would allow the generation of advanced algorithms and Machine Learning (ML) models utilising optical signal feature extraction techniques. The resulting model will be implemented in translating the optical signals into absolute measurements of ICP.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Pilot Study to Estimate Intracranial Pressure Noninvasively in Traumatic Brain Injury Patients
Actual Study Start Date :
Jan 20, 2020
Actual Primary Completion Date :
Jul 20, 2021
Actual Study Completion Date :
Jul 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: TBI-ICP monitoring

Optical signals acquisition from the nICP probe stuck to the patient's forehead

Device: nICP
The nICP probe contains infrared light sources that illuminate the deep brain tissue of the frontal lobe. Photodetectors in the probe detect the backscattered light, which is modulated by pulsation of the cerebral arteries.

Outcome Measures

Primary Outcome Measures

  1. Machine learning model agreement [48 hours record per patient]

    Bland-Altman limits of agreement between the offline estimation of nICP and the invasive ICP measurements

Secondary Outcome Measures

  1. Machine learning model diagnostic accuracy [48 hours record per patient]

    Sensitivity and specificity of the offline nICP estimation to identify ICP values over 20 mmHg

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient admitted to the Royal London Hospital who is having invasive ICP monitoring as part of their normal medical care

  • Subject is able to understand the risks and potential benefits of participating in the study and is willing to provide written informed consent. If the patient is unconscious, and a consultee is not available then a professional consultee (a doctor looking after the patient who is not involved in the trial) will assent to inclusion in the trial and non-invasive ICP monitoring will be performed.

Exclusion Criteria:
  • Patients with decompressive craniectomy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Royal London Hospital London England United Kingdom E1 1BB

Sponsors and Collaborators

  • Crainio Ltda
  • City, University of London
  • Barts & The London NHS Trust
  • National Institute for Health Research, United Kingdom

Investigators

  • Principal Investigator: Christopher Uff, FRCS, Consultant Neurosurgeon (Royal London Hosptial)

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Crainio Ltda
ClinicalTrials.gov Identifier:
NCT05632302
Other Study ID Numbers:
  • 219476
First Posted:
Nov 30, 2022
Last Update Posted:
Nov 30, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Crainio Ltda
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 30, 2022